HIV-1 Env Fusion Peptide Immunogens and Their Use


Millions of people are infected with HIV-1 worldwide, and 2.5 to 3 million new infections have been estimated to occur yearly. Although effective antiretroviral therapies are available, millions succumb to AIDS every year, especially in Sub-Saharan Africa, underscoring the need to develop measures to prevent the spread of this disease.

HIV-1 is an enveloped virus, which hides from humoral recognition behind a wide array of protective mechanisms. During infection, the major envelope protein of HIV-1 is cleaved by host cell proteases into two smaller versions (gp120 and gp41). Together gp120 and gp41 make up the HIV-1 Env spike, which is a target for neutralizing antibodies. It is believed that immunization with an effective immunogen based on the HIV-1 Env glycoprotein can elicit a neutralizing response, which may be protective against HIV-1 infection.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases used knowledge from the crystal structure of an HIV-1 neutralizing antibody, VRC34.01, in complex with its epitope on the HIV-1 Env trimer, to develop novel immunogens. HIV-1 uses a fusion peptide, located at the N-terminus of the gp41 subunit, to fuse with a target cell to infect the cell. The crystal structure revealed the epitope recognized by VRC34.01 to be composed primarily of the exposed 8 residues of the fusion peptide at the N-terminus of the gp41 subunit. Researchers designed fusion peptide immunogens that were comprised of the exposed residues of the fusion peptide coupled to highly immunogenic carrier proteins to focus the immune response to this conserved site of vulnerability. The fusion peptide can be displayed on scaffold proteins and – when coupled to HIV-1 Env trimer boosts – has the potential to elicit antibodies capable of neutralizing diverse HIV-1 strains in mice, guinea pigs and rhesus macaques, and might therefore serve as the basis for an effective HIV vaccine.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.

Potential Commercial Applications: Competitive Advantages:
  • HIV-1 vaccine
 
  • Potential to be a broadly neutralizing HIV-1 vaccine


Inventors:

Peter Kwong (NIAID)  ➽ more inventions...

Baoshan Zhang (NIAID)  ➽ more inventions...

Chang Choi (NIAID)  ➽ more inventions...

Rui Kong (NIAID)  ➽ more inventions...

Kevin Liu (NIAID)  ➽ more inventions...

John Mascola (NIAID)  ➽ more inventions...

Kai Xu (NIAID)  ➽ more inventions...

Tongqing Zhou (NIAID)  ➽ more inventions...

Priyamvada Acharya (NIAID)  ➽ more inventions...

Gwo-Yu Chuang (NIAID)  ➽ more inventions...

Michael Joyce (NIAID)  ➽ more inventions...

Cheng Cheng (NIAID)  ➽ more inventions...

Li Ou (NIAID)  ➽ more inventions...

Wing-pui Kong (NIAID)  ➽ more inventions...

Yongping Yang (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 62/403,266
PCT Application No. PCT/US2017/054959
US Application No. 16/338,964

Publications:
Kong R, et al. PMID: 27174988
Xu K, et al. PMID: 29867235

Licensing Contact:
Barry Buchbinder, Ph.D.
Email: BBuchbinder@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-279-2016-0
Updated: Oct 17, 2018